BR0313550A - modulação "antisense" da expressão de sintetase 1 de acil-coa - Google Patents
modulação "antisense" da expressão de sintetase 1 de acil-coaInfo
- Publication number
- BR0313550A BR0313550A BRPI0313550-0A BR0313550A BR0313550A BR 0313550 A BR0313550 A BR 0313550A BR 0313550 A BR0313550 A BR 0313550A BR 0313550 A BR0313550 A BR 0313550A
- Authority
- BR
- Brazil
- Prior art keywords
- expression
- antisense
- modulation
- acs1
- acyl
- Prior art date
Links
- 101000799318 Homo sapiens Long-chain-fatty-acid-CoA ligase 1 Proteins 0.000 title abstract 4
- 102100033995 Long-chain-fatty-acid-CoA ligase 1 Human genes 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
- C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MODULAçãO 'ANTISENSE' DA EXPRESSãO DE SINTETASE 1 DE ACIL-COA". São proporcionados compostos 'antisense', composições e métodos para modulação da síntese de acil-Coa 1, daqui em diante refeida como ACS1. As composições compreendem compostos 'antisense', particularmente oligonucleótidos 'antisense', tendo como alvo ácidos nucleicos codificadores de ACS1. São proporcionados métodos de utilização destes compostos para a modulação da expressão de ACS1 e para o tratamento de doenças associadas à expressão de ACS1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40359102P | 2002-08-14 | 2002-08-14 | |
PCT/US2003/025389 WO2004016749A2 (en) | 2002-08-14 | 2003-08-14 | Antisense modulation of acyl-coa synthetase 1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313550A true BR0313550A (pt) | 2006-06-13 |
Family
ID=31888248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0313550-0A BR0313550A (pt) | 2002-08-14 | 2003-08-14 | modulação "antisense" da expressão de sintetase 1 de acil-coa |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1572713A4 (pt) |
JP (1) | JP2006506976A (pt) |
AU (1) | AU2003269962A1 (pt) |
BR (1) | BR0313550A (pt) |
CA (1) | CA2495037A1 (pt) |
MX (1) | MXPA05001837A (pt) |
WO (1) | WO2004016749A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090221671A1 (en) * | 2005-05-24 | 2009-09-03 | Sanjay Pandey | Modulation of lmw-ptpase expression |
WO2010079819A1 (ja) * | 2009-01-08 | 2010-07-15 | 塩野義製薬株式会社 | 肥満または糖尿病治療用医薬組成物 |
JP2015082971A (ja) * | 2012-02-10 | 2015-04-30 | 国立大学法人大阪大学 | Acsl1に対するアンチセンスオリゴヌクレオチド |
WO2015020194A1 (ja) * | 2013-08-09 | 2015-02-12 | 国立大学法人大阪大学 | Acsl1に対するアンチセンスオリゴヌクレオチド |
WO2018181428A1 (ja) | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | 核酸医薬及び多分岐脂質の複合体 |
US20220267778A1 (en) | 2019-07-30 | 2022-08-25 | Shionogi & Co., Ltd. | Nucleic acid drug targeting murf1 |
JPWO2021256297A1 (pt) | 2020-06-15 | 2021-12-23 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
WO2003054159A2 (en) * | 2001-12-19 | 2003-07-03 | Exelixis, Inc. | Modulating insulin receptor signaling through targeting facl |
-
2003
- 2003-08-14 MX MXPA05001837A patent/MXPA05001837A/es not_active Application Discontinuation
- 2003-08-14 CA CA002495037A patent/CA2495037A1/en not_active Abandoned
- 2003-08-14 JP JP2004529376A patent/JP2006506976A/ja not_active Ceased
- 2003-08-14 BR BRPI0313550-0A patent/BR0313550A/pt not_active Application Discontinuation
- 2003-08-14 EP EP03751855A patent/EP1572713A4/en not_active Withdrawn
- 2003-08-14 AU AU2003269962A patent/AU2003269962A1/en not_active Abandoned
- 2003-08-14 WO PCT/US2003/025389 patent/WO2004016749A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004016749A2 (en) | 2004-02-26 |
AU2003269962A8 (en) | 2004-03-03 |
JP2006506976A (ja) | 2006-03-02 |
CA2495037A1 (en) | 2004-02-26 |
AU2003269962A1 (en) | 2004-03-03 |
WO2004016749A3 (en) | 2004-08-26 |
MXPA05001837A (es) | 2005-04-19 |
EP1572713A4 (en) | 2006-05-24 |
EP1572713A2 (en) | 2005-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001290706A1 (en) | Antisense modulation of clusterin expression | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
DK1250455T3 (da) | Antisense-inhibering af PTP1B-ekspression | |
DK1117672T3 (da) | Antisense-modulation af survivin-ekpression | |
WO2004044181A3 (en) | Antisense modulation of apolipoprotein b expression | |
WO2004011610A3 (en) | Antisense modulation of polo-like kinase expression | |
WO2003097662A8 (en) | Antisense modulation of apolipoprotein b expression | |
WO2003046132A3 (en) | Antisense modulation of myd88 expression | |
DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
BR0313455A (pt) | modulação "antisense" da expressão de nav1.3 | |
WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
WO2003053341A3 (en) | Antisense modulation of ship-1 expression | |
WO2003104397A3 (en) | ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION | |
BR0313550A (pt) | modulação "antisense" da expressão de sintetase 1 de acil-coa | |
WO2002095053A3 (en) | Antisense modulation of src-c expression | |
WO2003052062A3 (en) | Antisense modulation of cd36l1 expression | |
WO2003027229A3 (en) | Antisense modulation of rip2 expression | |
WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION | |
WO2002041836A3 (en) | Antisense modulation of src-1 expression | |
WO2003105754A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION | |
WO2003031576A3 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
WO2004015126A3 (en) | Antisense modulation of edg1 expression | |
WO2003099204A3 (en) | Antisense modulation of inhibitor-kappa b kinase-beta expression | |
WO2002040637A3 (en) | Antisense modulation of pi3k p85 expression | |
WO2004011623A3 (en) | Antisense modulation of ptpra expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |